Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical validation appears to be a matter of time. Read More
Equillium Inc. is advancing EQ-504, a potent aryl hydrocarbon receptor (AhR) modulator acquired through the acquisition of Ariagen Inc., a company that was majority owned by Equillium’s largest investor, Decheng Capital. Read More
BLR Bio LLC has announced new data on BLR-200, its lead compound for systemic sclerosis and lung fibrosis. In the new study, BLR-200 demonstrated the ability to reduce key disease tissue markers for fibrotic lung disease. Read More
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the uncertainty, BioWorld continues to cover the administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe. It’s all right here at Trump administration impacts. Read More
BioWorld is pleased to begin providing a new quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. NMEs include compounds chosen for further pharmacological evaluation or as clinical candidates; new leads whose structural optimization could provide new therapeutic agents; new additions to the structural diversity of known mechanistic classes of drugs; and new pharmacological tools for investigating drug targets. Read More
Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. Read More
The transcriptional repressor B-cell lymphoma 6 (BCL6) plays a central role in the development and progression of various B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), where it is associated with poor prognosis and resistance to standard immunochemotherapy. Read More
The use of mimicking antibodies that activate death receptors (DRs) to selectively induce cell death in cancer cells has shown limited clinical success so far, primarily due to suboptimal efficacy and safety concerns, particularly hepatotoxicity. Emerging strategies to enhance efficacy include the development of bispecific antibodies that simultaneously target DRs and tumor-specific antigens. Read More
Breast cancer was the second most frequent cause of new cancer cases worldwide in 2024, and up to 20% of cases fall under the subtype of triple-negative breast cancer (TNBC), one of the most aggressive and difficult subtypes to treat. Read More
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer. Read More
The leucine-rich repeat-containing protein 15 (LRRC15) is a cell surface protein involved in cell-cell and cell-matrix interactions, with limited expression in normal tissues. Read More
Fauna Bio Inc. has identified 5-HT3 receptor antagonists reported to be useful for the treatment of cardiovascular and respiratory disorders. Read More
Scientists at Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, LEOPARD and Noonan syndromes. Read More
Triple-negative breast cancer (TNBC), which accounts for up to 20% of cases of breast cancer, is one of the most aggressive and difficult to treat subtypes of the disease. Read More
Raythera Inc. has described C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, atherosclerosis, asthma, chronic obstructive pulmonary disease and multiple sclerosis, among others. Read More
